Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes
The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes
Status: Enrolling
Updated:  4/27/2016
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes
The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes
Status: Enrolling
Updated: 4/27/2016
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes
The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes
Status: Enrolling
Updated:  4/27/2016
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes
The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes
Status: Enrolling
Updated: 4/27/2016
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Relationship Between Gastric Emptying and Glycemic Variability in Type 1 Diabetes Mellitus
Relationship Between Gastric Emptying and Glycemic Variability in Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  4/27/2016
The Mayo Clinic
mi
from
Rochester, MN
Relationship Between Gastric Emptying and Glycemic Variability in Type 1 Diabetes Mellitus
Relationship Between Gastric Emptying and Glycemic Variability in Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 4/27/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Aerobic Plus Resistance Training and Insulin Sensitivity in African American Men
Aerobic Plus Resistance Training and Insulin Sensitivity in African American Men
Status: Enrolling
Updated:  5/2/2016
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Aerobic Plus Resistance Training and Insulin Sensitivity in African American Men
Aerobic Plus Resistance Training and Insulin Sensitivity in African American Men
Status: Enrolling
Updated: 5/2/2016
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Little Rock, AR
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Los Angeles, CA
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Los Angeles, CA
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Aurora, CO
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Aurora, CO
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
New Haven, CT
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Jacksonville, FL
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Indianapolis, IN
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Lenexa, KA
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Lenexa, KA
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Baltimore, MD
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Kansas City, MO
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Toledo, OH
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Houston, TX
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated:  5/2/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated:  5/2/2016
mi
from
Campinas,
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Status: Enrolling
Updated: 5/2/2016
mi
from
Campinas,
Click here to add this to my saved trials
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated:  5/9/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated:  5/9/2016
Children's Hospital of Orange County
mi
from
Orange, CA
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated:  5/9/2016
University of California at San Francisco
mi
from
San Francisco, CA
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated:  5/9/2016
Indiana University-Riley Hospital for Children
mi
from
Indianapolis, IN
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Indiana University-Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated:  5/9/2016
University of Iowa Health Care
mi
from
Iowa City, IA
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
University of Iowa Health Care
mi
from
Iowa City, IA
Click here to add this to my saved trials
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated:  5/9/2016
Joslin Diabetes Center
mi
from
Boston, MA
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Joslin Diabetes Center
mi
from
Boston, MA
Click here to add this to my saved trials
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated:  5/9/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated:  5/9/2016
Children's Mercy Hospital
mi
from
Kansas City, MO
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated:  5/9/2016
Utah Diabetes Center
mi
from
Salt Lake City, UT
Nutritional Intervention to Prevent Diabetes
Status: Enrolling
Updated: 5/9/2016
Utah Diabetes Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator
Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator
Status: Enrolling
Updated:  5/10/2016
University of Virginia, Center for Diabetes Technology
mi
from
Charlottesville, VA
Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator
Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator
Status: Enrolling
Updated: 5/10/2016
University of Virginia, Center for Diabetes Technology
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator
Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator
Status: Enrolling
Updated:  5/10/2016
VCU Medical Center
mi
from
Richmond, VA
Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator
Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator
Status: Enrolling
Updated: 5/10/2016
VCU Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide
Status: Enrolling
Updated:  5/10/2016
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide
Status: Enrolling
Updated: 5/10/2016
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  5/12/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  5/12/2016
University of California at San Francisco
mi
from
San Francisco, CA
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  5/12/2016
Stanford Univ Med Ctr
mi
from
Stanford, CA
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  5/12/2016
Barbara Davis Center for Childhood Diabetes
mi
from
Denver, CO
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Barbara Davis Center for Childhood Diabetes
mi
from
Denver, CO
Click here to add this to my saved trials
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  5/12/2016
University of Florida
mi
from
Gainesville, FL
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  5/12/2016
University of Miami School of Medicine
mi
from
Miami, FL
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
University of Miami School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  5/12/2016
Riley Hospital for Children
mi
from
Indianapolis, IN
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  5/12/2016
Joslin Diabetes Center
mi
from
Boston, MA
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Joslin Diabetes Center
mi
from
Boston, MA
Click here to add this to my saved trials
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  5/12/2016
Univ of Minnesota
mi
from
Minneapolis, MN
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  5/12/2016
Naomi Berrie Diabetes Center (Columbia University)
mi
from
New York, NY
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Naomi Berrie Diabetes Center (Columbia University)
mi
from
New York, NY
Click here to add this to my saved trials
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  5/12/2016
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  5/12/2016
UT Southwestern Medical Center
mi
from
Dallas, TX
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
UT Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  5/12/2016
Benaroya Research Institute at Virginia Mason
mi
from
Seattle, WA
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
Benaroya Research Institute at Virginia Mason
mi
from
Seattle, WA
Click here to add this to my saved trials
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  5/12/2016
University of Bristol
mi
from
Bristol,
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 5/12/2016
University of Bristol
mi
from
Bristol,
Click here to add this to my saved trials
Feet First: Promoting Physical Activity Among People With Diabetes Mellitus and Insensate Feet
Feet First: Increasing Activity Without Increasing the Risk of Foot Ulcers in People With Diabetes and Insensate Feet
Status: Enrolling
Updated:  5/12/2016
University of Missouri
mi
from
Columbia, MO
Feet First: Promoting Physical Activity Among People With Diabetes Mellitus and Insensate Feet
Feet First: Increasing Activity Without Increasing the Risk of Foot Ulcers in People With Diabetes and Insensate Feet
Status: Enrolling
Updated: 5/12/2016
University of Missouri
mi
from
Columbia, MO
Click here to add this to my saved trials
A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation
A Single-Center, Randomized, Open-Label, 2-Period Complete Crossover Study to Compare the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation in Healthy Adult Subjects
Status: Enrolling
Updated:  5/17/2016
Medpace
mi
from
Cincinnati, OH
A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation
A Single-Center, Randomized, Open-Label, 2-Period Complete Crossover Study to Compare the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation in Healthy Adult Subjects
Status: Enrolling
Updated: 5/17/2016
Medpace
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion
A Randomized, 2X4 Week, Active-Controlled, Open-Label, 2-Treatment Arm, 2-Period Cross-Over Study Assessing the Safety of SAR342434 and Humalog® Used in Continuous Subcutaneous Insulin Infusion (CSII) in Adult Patients With Type 1 Diabetes Mellitus (T1DM)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Little Rock, AR
Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion
A Randomized, 2X4 Week, Active-Controlled, Open-Label, 2-Treatment Arm, 2-Period Cross-Over Study Assessing the Safety of SAR342434 and Humalog® Used in Continuous Subcutaneous Insulin Infusion (CSII) in Adult Patients With Type 1 Diabetes Mellitus (T1DM)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion
A Randomized, 2X4 Week, Active-Controlled, Open-Label, 2-Treatment Arm, 2-Period Cross-Over Study Assessing the Safety of SAR342434 and Humalog® Used in Continuous Subcutaneous Insulin Infusion (CSII) in Adult Patients With Type 1 Diabetes Mellitus (T1DM)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Denver, CO
Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion
A Randomized, 2X4 Week, Active-Controlled, Open-Label, 2-Treatment Arm, 2-Period Cross-Over Study Assessing the Safety of SAR342434 and Humalog® Used in Continuous Subcutaneous Insulin Infusion (CSII) in Adult Patients With Type 1 Diabetes Mellitus (T1DM)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials